Use of intravenous acetylsalicylic acid (‘Aspirin’) as a novel antidote for human paraquat poisoning- can it reduce the 70% mortality rate and oxidative stress?

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

SLCTR

Registry ID

SLCTR/2009/001

Enrollment

Registered

2009-01-16

Start date

2009-03-02

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Paraquat self poisoning

Interventions

Consenting patients will be given ASA in addition to the standard treatment. Dose of ASA will be calculated as 100mg/Kg. This will be given as an IV infusion over 1 hour. This will be followed up with

Eligibility

Inclusion criteria

Inclusion criteria: Paraquat self poisoning presenting within 24 hours and a positive urine dithionite test

Exclusion criteria

Exclusion criteria: Age under 14 years pregnanacy presenting after 24 hours known aspirin allergy

Design outcomes

Primary

Measure	Time frame
Measure of oxidative markers as outlined before 3. Plasma and EBC 4-Hydroxy-2-nonenal and F2?-isoprostane concentrations (GC/MS) 4. Plasma and EBC proteins CC16 and SP-D (Assay kits) 5. EBC Hydrogen peroxide concentrations (Assay kit) 6. EBC Thiobarbituric Acid Reactive Substances (TBARS) (spectrophotometric assay) 7. EBC Proteomic 8. Urinary F2?-isoprostane and prostacyclin levels []	—

Secondary

Measure	Time frame
Death []	—

Countries

Sri Lanka

Contacts

Public ContactIndika Gawarammana

Senior Lecturer and Consultant Physician

indika@sactrc.org

Outcome results

None listed

Source: SLCTR (via WHO ICTRP) · Data processed: Aug 9, 2026